Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

PURPOSE: We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib. MATERIALS AND METHODS: We analyzed patients trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Youjin, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Sun, Jong-Mu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473268/
https://www.ncbi.nlm.nih.gov/pubmed/29898592
http://dx.doi.org/10.4143/crt.2018.117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473268/
https://www.ncbi.nlm.nih.gov/pubmed/29898592
http://dx.doi.org/10.4143/crt.2018.117

Ejemplares similares